Charity registration number 1157884 (England and Wales)

AMR ACTION UK

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

AMR ACTION UK

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Ms Rosemary Howell* Ms Ghada Zoubiane Dr Christine Richardson Dr Peter Kirkpatrick* Ms Clare Kerr Ms Rose Gray*
Chief Executive Officer	Kirsteen Wills
Charity number (England and Wales)	1157884
Principal address	167-169 Great Portland Street 5th Floor London W1W 5PF
Independent examiner	Tom Wilcox Counterculture Partnership LLP 23 St Leonards Road Bexhill-on-Sea East Sussex TN40 1HH

*Also, member of the Finance Committee

AMR ACTION UK

CONTENTS

	Page
Trustees' report	1 - 6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the financial statements	10 - 20

AMR ACTION UK

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

The trustees present their annual report and financial statements for the year ended 31 December 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

Objectives and activities
Who we are and what we do

AMR Action UK is the Patient Organisation (PO) for Antimicrobial Resistance (AMR) in the UK. The charity works to prevent the harm from the impacts of antimicrobial resistance to people in the four nations of the United Kingdom and campaigns for policy changes and for changes in healthcare practice which benefit patients and families. The charity's work is informed by our patient and public engagement, our direct support of patients through our services and through our patient-centred research activities.

About antibiotic and antimicrobial resistance

Antibiotic resistance, that is when infectious bacteria become resistant to antibiotic treatment, is on the rise globally. Antimicrobial resistance (AMR) is a broader term that includes bacteria, viruses, fungi and parasites that develop resistance to antimicrobial medicines. An article published in *The Lancet* in 2022 estimated that, in 2019, 1.27 million people died globally directly from an antibiotic resistant infection (Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al, "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis", *The Lancet*, 2022; 399 (10325):629-5), a figure higher than people dying from HIV or malaria. This figure is alarming and whilst the highest number of deaths were in lower and middle income countries, COVID has shown us how quickly an infectious agent can spread around the globe.

According to the Institute for Health Metrics and Evaluation (IHME), in 2019 there were 7,600 deaths attributable to antimicrobial resistance (AMR) and 35,200 deaths associated with AMR in the UK (see "The burden of AMR in the UK" by IHME, University of Washington, University of Oxford and Global Research on Antimicrobial Resistance; available from https://www.healthdata.org/antimicrobial-resistance/policy-briefings). The IHME report also points out that the number of UK deaths from AMR is "higher than deaths from digestive diseases, diabetes and kidney diseases, other non-communicable diseases, unintentional injuries, and self-harm and interpersonal violence".

Purpose

The charity's purposes are set out in its constitution, as follows:

"… to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters."

Public benefit
The charity delivers public benefit through its four pillars of activity:

1. Direct support of people (patients and carers) whose lives are impacted by resistant infections.
2. Patient and carer engagement – ensuring patients and carers are engaged in the decisions that matter to them.
3. Patient-centred research in relation to the prevention of resistant infections, their treatment and support for those living with resistant infections as long-term conditions.

plus

4. Our work to influence policymakers, and to change practices within healthcare systems, including the NHS.

The charity regularly reviews how its activities have benefited those groups of people we are set up to help, referring to the Charity Commission's guidance on public benefit.

Achievements and performance

In early 2024, under its previous leadership team, the charity decided to focus strongly on one of the key areas of patient concern that came to us via our patient support service – chronic and recurring Urinary UTI's.

Up to 50% of women will suffer from an acute UTI at some point in their life, with 20-30% of women who have had a UTI being subject to a recurrence. In the UK, UTI's are the second most common healthcare associated infection (an infection acquired from a healthcare setting such as a hospital), accounting for 17.2% of all such infections. UT's are also a major driver of antibiotic prescribing in primary care, with multidrug resistant infections rising. In addition, UTI's are one of the most common causes of sepsis as diagnosed/treated in hospitals, which can be fatal.

While often regarded as a mild 'bladder complaint', the numbers of patients experiencing recurrent and chronic/ complex UT's, due to the infection becoming resistance to antibiotic treatment, is growing. The impact of a drug-resistant UTI upon a patient can be life changing. Those who contact our charity for support tell us of ongoing pain, misdiagnosis, and the impact that drug-resistant infections have on their lives.

In the summer of 2024, working in partnership with James Lind Alliance and with two other charities, we launched the Priority Setting Partnership for chronic and recurrent UTI's. This ground-breaking piece of work was planned to be the collective view of patients and medical professionals as to the research that is currently missing in this important area and how these research areas should be prioritised, with this information available to Universities, and other researchers, to inform their future research programmes. The preliminary results of this work were announced at the charity's conference for 18 September 2025 '*Advances in Chronic and Recurrent UTIs',* with a final report in early 2026.

Within Patient Services, individuals living with resistant infections and their families continued to receive personalised support and information from our Patient Support Team, via phone, email, plus on-line peer support sessions to help them to access treatment and support as well as to live with the chronic impacts of AMR-related conditions.

New initiatives for 2025 included the launch of the charity's "Patient Panels", initially in England and in Wales. These panels have been designed to provide a space for patients and carers to have their voices heard on AMR-related topics that matter to them, and to provide a link through which both internal functions, such as advocacy, and external organisations, can consult with patients. Also launched in 2025 was our new commercial offer to the AMR sector – a mechanism through which researchers can engage with the AMR patient community on a paid-basis, with the income deriving from the activity subsidising the charity's services.

Meanwhile, at a policy level, Antibiotic resistance, and AMR more widely, remains a major global health issue, on a par with climate change, but receiving far less attention. In May 2024 the UK's National AMR Action Plan was published, detailing actions that will be taken across the four nations of the United Kingdom – England, Scotland, Wales and Northern Ireland – to prevent the growth of AMR and those affected by it and to improve treatment. A national Board overseas the implementation of the plan. In early 2025 the charity was part of a small group that helped define how patient representation should be organised in relation to national Boards for people with long-term conditions, including AMR, resulting in 3 patient representatives being appointed to the NHS England AMR National Board. The charity was also delighted to take up a place on the National Board representing third sector organisations (charities).

In November 2025 the charity launched a campaign focussed on what could be done *Right here:Right now* in the UK to prevent resistant infections and improve treatment, which runs through 2026.

Fundraising

The fundraising environment in 2025 continued to be challenging for the charity with donations affected by the cost-of-living crisis and changes in the way in which grant funders operate. We were pleased to continue to receive support from the National Lottery Fund for the continuation of our Patient Support Services, but with a change of National Lottery strategy away from small scale national charities to local charities we know that this will not be a funding source available to us in the future. Similarly, although we have some core funding available until June 2026 through the Oak foundation, this is another funder whose generous contribution will have to be replaced after that.

At the same time, there are major changes in how grant-funding is now working. The competition for grants has intensified as charities have seen their other sources of income reduce, but simultaneously, many trusts and foundations are now accepting applications for funding on an invitation basis only. In response to the increased challenges in this area, the charity will employ a full-time Trusts and Grants fundraiser in 2026.

We are fortunate to have continued in 2025 to benefit from a range of donations and sponsorships from the corporate sector. These included:

- £20,071 from A. Menarini Farmaceutica Internazionale SRL to host our follow-up conference “Living with Chronic and Complex UTI” in September 2025, also supported by Pfizer Limited who contributed £14,071 in 2024.
- £10,000 from Mölnlycke Health Care AB, and £5,000 from each of B. Braun Medical Ltd and Cepheid UK Ltd, as contributors to the Circles Programme.

The above corporate sponsorship and grants added to contributions made in 2024 by supporters Advanz Pharma, GSK, and Shionogi.

As always, we are enormously grateful to those who donated and volunteered on our behalf. Without their support we would, quite simply, not be able to continue our vital work.

Financial review

The consolidated gross income for the year was £369,284 (2024 £406,889). The consolidated net movement in funds for the year was a loss of £94,850 (2024 63,928). There were no significant, unexpected expenditure items, but rather the loss in net funds was due to the spending of historic restricted funds.

Going concern

The organisation works to an annual budget and has prepared a financial plan to the end of December 2026 to ensure the organisation has sufficient funds in place to support the charity’s service delivery and advocacy activities for the next year.

With these measures in place, trustees are confident about the organisation’s ability to continue in operation for at least twelve months from the date of the financial statements. On this basis the Board has approved the preparation of the financial statements on a going concern basis.

Reserves policy

The trustees aim to maintain a minimum of free reserves equal to 3 months’ core expenditure (approximately £90,000). Any funds over this sum are used to fund the charity’s objects. The year-end level of free reserves was £125,504 (2024: £124,202). This level has risen steadily through early 2026 in line with our fundraising strategy.

Risk assessment and management

The charity regularly reviews risks relating to its operations. The main area of identified risk is financial sustainability when two multi-year grants finish in 2026, particularly in respect of pressure on unrestricted funds.

To address these risks measures have been put in place as follows:

1. A focus in the latter part of 2025, and for the first half of 2026, on generation of unrestricted income.
2. A review of operational areas of activity and the likelihood of being able to raise continuity/replacement funding during 2026.
3. Increased frequency of Finance Committee meetings in 2026 to ensure increased monitoring by Trustees of financial risks.

Plans for future periods

AMR Action UK will continue to build on the strategic work started with the revised strategy in 2025. Our vision is to create a world where microbial resistance is better understood and effectively managed, so patients are protected and the burden on health and social care minimised. The experience of patients and people who have suffered from resistant infections will continue to inform our work so that we can help to shape UK research, policy making and public education on antimicrobial resistance.

We will combine learning from our patient and carer communities with our extensive knowledge of the UK political and NHS landscapes. This will enable us to advocate for the changes that will make the most difference to people at risk of resistant infections, or suffering the long-term impact of having experienced a treatment resistant infection.

Women can suffer from a higher burden of infections, and particularly infections that are resistant to treatment. Across the UK, women receive the majority of antibiotics prescribed in the community. They are more likely to experience recurrent infections such as UTIs – a leading source of resistant bloodstream infections. From pregnancy through to later life, repeated antibiotic exposure builds, which can increase the risk of a resistant infection.

Through our advocacy and campaigning we will provide support for individual women, and bring their lived experience to the centre of policy and research on this issue. We will ensure women affected are heard. We will help them go from ignored to empowered.

Our patient insight panels have expanded across the nations of the UK, and these will continue to grow and develop.

National Patient Insight Panels provide an opportunity to:

- Join a national network of patients and caregivers
- Meet regularly to share insights on particular topics
- Influence AMR-related policy in England and each of the devolved nations
- Influence practice change in each of the four UK NHS systems

These patient insight panels provide an invaluable opportunity to really understand what and how people are challenged by recurrent infections. We will then share their lived experience to make positive and direct changes in policy and practice, that will benefit future patients.

As the UK’s leading patient charity for antimicrobial resistance, we are committed to putting patients at the heart of research and innovation. Our bespoke services will continue to support organisations to incorporate Patient and Public Involvement and Engagement (PPIE) in both their research and commercial projects.

We will offer flexible solutions, from sharing opportunities with our networks to delivering fully facilitated workshops. Our team can identify suitable participants, including any specific requirements based on demographics, medical conditions and diversity – saving researchers time, while ensuring compliance with GDPR and quality standards under bespoke agreements.

We will help with:

- Recruitment of participants across all UK countries, communities, and groups
- Representation that reflects diversity and inclusion
- Fully facilitated workshops – online or in person
- Letters of support for research projects aligned with our mission

Our work will continue to focus on the changes that can be implemented now, in all four nations of the United Kingdom. These changes will prevent the avoidable harms from resistant infections, and ensure people receive the treatment they need to reduce harm. We will help prevent life-changing damage to health, improve health outcomes, and prevent unnecessary deaths.

Structure, governance and management

Constitution and Trustee recruitment and appointment

Antibiotic Research UK was registered as a charitable incorporated organisation (CIO) on 16 July 2014. At an EGM on 2nd May 2025, by a unanimous vote, a name change for the charity was approved by members. It is now called AMR action UK. This change of name was to reflect the much wider range of work which the charity now undertakes.

The work, management, finances and strategy of the charity are overseen by a Board of Trustees. The Trustees who held office during the financial year and at the date of the report are set out on page 1. The constitution requires there to be a minimum of three Trustees and a maximum of twelve Trustees in office at any one time. Trustees that are appointed at an annual general meeting (AGM) retire from office after a full term of three years, at the following AGM. However, Trustees that are appointed directly by the Board of Trustees in-between AGMs must step down at the next AGM, but can stand for re-election at that AGM, and if so re-elected, their first three-year term of office starts at that point. A Trustee can seek re-election for a further three-year term of office but not a third term without an interval of a year.

Purpose

The charity's purposes are set out in its constitution, as follows:

"… to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters."

Much has changed since the charity's incorporation. At the Charity's AGM in September 2026 the Trustees will propose a new constitution for the charity which reflects current charity law, a more comprehensive description of the charity's activities, so that this is clearer to prospective funders, and more inclusive language.

The trustees who served during the year and up to the date of signature of the financial statements were:

Mr Simon Dukes* (Chair) (Resigned 30 June 2025)
Ms Rosemary Howell*
Ms Ghada Zoubiane
Dr Christine Richardson
Dr Peter Kirkpatrick*
Ms Clare Kerr
Ms Rose Gray*

Board and management operations and structure

Board of Trustees

The Board of Trustees meets at least four times a year to review the organisation's work, finances and services, and to agree the strategic goals for the charity. The Chief Executive Officer attends most meetings.

A Finance Committee and comprising at least three Trustees, meets quarterly to monitor and scrutinise the charity's financial performance, including its approach to management of funds, treasury and reserves. Recommendations from this committee are presented to the full Board of Trustees.

The Board also operated an advisory committee during 2025 called the Science, Education and Policy Committee. This committee had oversight of, and could give specialist advice in respect of, the charity's research programme. This committee comprises a mix of trustees and specialist advisors. The role of this committee will be reviewed in 2026.

Recruitment and appointment of new trustees


An annual review of the recruitment needs of the Board of Trustees is carried out under the leadership of the Chair, including an audit of the current knowledge, experience, skills and abilities, and how the Board will be affected by any planned trustee departures in the future. Any Trustee vacancies are advertised nationally, and via relevant professional and organisational networks, including the charity's own supporter base, depending upon the expertise and specialisms required. Applicants are shortlisted against the criteria in the person specification for the role of Trustee, including any specific qualities highlighted during the above audit. Shortlisted applicants are invited for interview by at least two Trustees, one of whom will be the chair. Shortlisted applicants are only appointed where they have the necessary skills and qualities to contribute effectively to the charity's governance and development. All new Trustees receive thorough induction and training, which includes information about the organisation's constitution, accounts, financial reports and minutes of previous Trustees' meetings. During 2025 Trustees accepted the recommendations of the CEO to seek appointment of a Treasurer and of a registered medical practitioner to the charity's board.

Also in 2025, Simon Dukes retired as Chair We are grateful to Simon for his support of the Charity through times of considerable change and also to Rosemary Howell, who stepped into the position of Interim Chair while an open recruitment was carried out.

Management and organisation

Day-to-day operation of the charity, and strategy implementation, is delegated to the Chief Executive Officer, who works for the charity on a part-time basis. The CEO is supported by a small team of employees engaged in patient support, patient engagement and office support. The charity also has a small fundraising team focussed on creating a sustainable income stream so that the charity can both continue with, and grow, its vital work.

The trustees' report was approved by the Board of Trustees.



Ms Rosemary Howell*
Interim Chair

Date: 17/09/2026

AMR ACTION UK

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF AMR ACTION UK

I report to the trustees on my examination of the financial statements of AMR Action UK (the charity) for the year ended 31 December 2025.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011.

I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

Independent examiner's statement

Since the charity's gross income exceeded £250,000, the independent examiner must be a member of a body listed in section 145 of the Charities Act 2011. I confirm that I am qualified to undertake the examination because I am a member of Fellow Member of the Association of Charity Independent Examiners, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn. I understand that this has been done in order for the financial statements to provide a true and fair view in accordance with UK Generally Accepted Accounting Practice.


I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1 accounting records were not kept in respect of the charity as required by section 130 of the Charities Act 2011.

2 the financial statements do not accord with those records; or

3 the financial statements do not comply with the applicable requirements concerning the form and content of financial statements set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Tom Wilcox
Counterculture Partnership LLP
23 St Leonards Road
Bexhill-on-Sea
East Sussex
TN40 1HH
Date: 18/09/2026

AMR ACTION UK

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2025

	Notes	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Income from:							
Donations and legacies	**3**	61,552	-	61,552	41,762	-	41,762
Charitable activities	**4**	186,850	112,595	299,445	218,210	118,716	336,926
Other trading activities	**5**	8,287	-	8,287	22,638	5,563	28,201
Total income		256,689	112,595	369,284	282,610	124,279	406,889
Expenditure on:							
Raising funds	**6**	84,048	50	84,098	97,662	1,630	99,292
Charitable activities	**7**	171,339	208,697	380,036	181,701	189,824	371,525
Total expenditure		255,387	208,747	464,134	279,363	191,454	470,817
Net income/(expenditure)		1,302	(96,152)	(94,850)	3,247	(67,175)	(63,928)
Transfers between funds		-	-	-	64,510	(64,510)	-
Net movement in funds	**9**	1,302	(96,152)	(94,850)	67,757	(131,685)	(63,928)
Reconciliation of funds:							
Fund balances at 1 January 2025		124,202	265,201	389,403	56,445	396,886	453,331
Fund balances at 31 December 2025		125,504	169,049	294,553	124,202	265,201	389,403

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.


AMR ACTION UK

BALANCE SHEET

AS AT 31 DECEMBER 2025

	Notes	2025 £	2025 £	2024 £	2024 £
Fixed assets					
Tangible assets	**13**		8,638		-
Current assets					
Debtors	**14**	5,198		14,276	
Cash at bank and in hand		396,671		543,853	
		401,869		558,129	
Creditors: amounts falling due within one year	**15**	(115,954)		(168,726)	
Net current assets			285,915		389,403
Total assets less current liabilities			294,553		389,403
The funds of the charity					
Restricted income funds	**18**		169,049		265,201
Unrestricted funds	**19**		125,504		124,202
			294,553		389,403

The financial statements were approved by the trustees on 17/09/2026



Ms Rosemary Howell*
Interim Chair

1 Accounting policies

1.1 Basis of preparation

The financial statements have been prepared in accordance with the charity's Memorandum of Association, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a statement of cash flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1 Accounting policies **(Continued)**

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment	20% on reducing balance basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

1 Accounting policies **(Continued)**

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Donations and gifts	61,552	41,762

3 Income from donations and legacies **(Continued)**

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Donations and gifts		
Donations	15,432	10,000
Gift Aid	4,889	6,044
Online giving	37,976	23,438
Tribute	3,255	2,280
	61,552	41,762

4 Income from charitable activities

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Charitable activities						
Trust and foundations	166,805	87,487	254,292	186,210	45,248	231,458
Corporate income	20,045	25,108	45,153	32,000	73,468	105,468
	186,850	112,595	299,445	218,210	118,716	336,926

5 Income from other trading activities

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Membership fees	2,908	-	2,908	3,342	-	3,342
Fundraising events	500	-	500	10,527	-	10,527
Other	4,879	-	4,879	8,769	5,563	14,332
Other trading activities	8,287	-	8,287	22,638	5,563	28,201

6 Expenditure on raising funds

	Unrestricted funds 2025	Restricted funds 2025	Total 2025	Unrestricted funds 2024	Restricted funds 2024	Total 2024
	£	£	£	£	£	£
Fundraising and publicity						
Fundraising expenses	446	50	496	3,578	-	3,578
Fundraiser fees	25,367	-	25,367	94,084	1,630	95,714
Fundraising staff costs	58,235	-	58,235	-	-	-
	84,048	50	84,098	97,662	1,630	99,292

7 Expenditure on charitable activities

	Total 2025	Total 2024
	£	£
Direct costs		
Staff costs	142,002	-
Depreciation and impairment	2,160	-
Direct Project Grant	39,664	65,693
Other Direct Project Costs	21,766	37,221
Other charitable expenditure	11,221	-
Computer software	9,791	7,766
Consultancy costs	39,904	112,113
Insurance	585	743
Printing, Postage & stationery	2,158	808
Website & IT	19,381	34,516
Phone & Internet	1,222	602
Travel & Subsistence	3,609	6,158
Bank charges	538	653
Recruitment Costs	5,064	3,750
Annual lecture	27,602	34,966
Sundry Costs	26	83
Other Legal & Professional Fees	46,534	49,158
	373,227	354,230
Share of support and governance costs (see note 8)		
Governance	6,809	17,295
	380,036	371,525
Analysis by fund		
Unrestricted funds	171,339	181,701
Restricted funds	208,697	189,824
	380,036	371,525

7 Expenditure on charitable activities **(Continued)**

In previous years, the work of the charity was mainly undertaken by contractors (consultants) however, this year the trustees decided to move to a model of employed staff and this is reflected in the figures above.

8 Support costs allocated to activities

	2025	2024
	£	£
Governance costs	6,809	17,295
Total	6,809	17,295

Governance costs comprise:	2025 £	2024 £
Independent examination fees	1,500	1,380
Accountancy	1,500	1,380
Legal and professional	3,809	14,535
	6,809	17,295

9 Net movement in funds

	2025	2024
	£	£
The net movement in funds is stated after charging/(crediting):		
Fees payable for the independent examination of the charity's financial statements	1,500	1,380
Depreciation of owned tangible fixed assets	2,160	-

10 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

11 Employees

The average monthly number of employees during the year was:

	2025	2024
	Number	Number
	9	-

11 Employees **(Continued)**

Employment costs	2025	2024
	£	£
Wages and salaries	188,035	-
Social security costs	10,290	-
Other pension costs	1,912	-
	200,237	-

There were no employees whose annual remuneration was more than £60,000.

12 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

13 Tangible fixed assets

	Computer equipment
	£
Cost	
Additions	10,798
At 31 December 2025	10,798
Depreciation and impairment	
Depreciation charged in the year	2,160
At 31 December 2025	2,160
Carrying amount	
At 31 December 2025	8,638

14 Debtors

	2025	2024
Amounts falling due within one year:	£	£
Trade debtors	4,997	5,001
Prepayments and accrued income	201	9,275
	5,198	14,276

15 Creditors: amounts falling due within one year

	Notes	2025 £	2024 £
Other taxation and social security		7,792	-
Deferred income	**16**	75,000	70,000
Trade creditors		28,358	24,168
Other creditors		-	67,342
Accruals		4,804	7,216
		115,954	168,726

16 Deferred income

	2025 £	2024 £
Arising from Oak Foundation	75,000	70,000

Deferred income is included in the financial statements as follows:

	2025 £	2024 £
Deferred income is included within:		
Current liabilities	75,000	70,000
Movements in the year:		
Deferred income at 1 January 2025	70,000	94,163
Released from previous periods	-	(24,163)
Resources deferred in the year	5,000	-
Deferred income at 31 December 2025	75,000	70,000

17 Retirement benefit schemes

Defined contribution schemes	2025 £	2024 £
Charge to profit or loss in respect of defined contribution schemes	1,912	-

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

18 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2025	Incoming resources	Resources expended	Transfers	At 31 December 2025
	£	£	£	£	£
Patient Support	8,101	-	(8,101)	-	-
Test Discs	4,101	-	-	-	4,101
Patient Videos	59,397	-	(26,521)	-	32,876
Small Research Grants	123,454	20,500	(37,102)	-	106,852
Mutate Trial	13,472	-	-	-	13,472
TNL England	1,707	66,987	(65,169)	-	3,525
PhD student support	25,000	-	(25,000)	-	-
PSO Digital Transformation	9,850	-	(7,767)	-	2,083
Annual Lecture	20,119	25,108	(39,087)	-	6,140
	265,201	112,595	(208,747)	-	169,049

Previous year:	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
Antibiotic Resistance Breakers	27,224	-	(5,830)	(21,394)	-
Patient Support	12,441	1,429	(5,769)	-	8,101
Test Discs	44,090	(30,915)	(9,074)	-	4,101
Combined Research 2019 including Test Discs	26,379	-	(4,530)	(21,849)	-
Small Research Grants	93,397	38,044	(28,046)	20,059	123,454
Mutate Trial	54,957	(21,426)	-	(20,059)	13,472
TNL England	654	60,292	(59,239)	-	1,707
PhD student support	52,175	(2,175)	(25,000)	-	25,000
Reducing Antibiotic Prescribing	24,842	-	(3,575)	(21,267)	-
PSO Digital Transformation	25,275	-	(15,425)	-	9,850
Annual Lecture	35,452	19,634	(34,966)	-	20,119
Patient Videos	-	59,397	-	-	59,397
	396,886	124,279	(191,454)	(64,510)	265,201

18 Restricted funds **(Continued)**

Notes to restricted funds

Antibiotic Resistance Breakers (ARB) fund represents monies donated to fund the research into ARBs, this incorporates the Holbeck Charitable Trust funding as it was for the same cause.

Patient Support fund represents monies donated to fund a patient support officer whose role will be to develop a portfolio of patient support resources for people affected by antimicrobial resistance.

Patient Videos funds donated towards the production of video case studies to capture lived experiences and perspectives of those living or working with antibiotic resistance for use in campaigns to drive change.

Test Discs funds represents monies donated towards the next stage of research. The manufacture and circulation to partners of a test disk sensitivity kit for further testing.

Combined Research 2019 Including Test Discs fund represents monies donated towards both of the above two funds.

Small Research Grants fund represents monies donated towards the small research grants programmes.

Mutate Trial fund represents monies donated for the next phase of the MUTATE research programme which is working with hospital microbiology labs in a round robin evaluation of cefepime / sulbactam test discs.

TNL England fund represents a National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in England.

PhD student support fund represents monies donated by the Troutsdale Trust to support a PhD student.

Reducing Antibiotic Prescribing through triaging using Point of Care testing fund represents monies donated for the Study Protocol Development and planning for the scaled up roll out of the study.

PSO – Digital Transformation fund is towards the developing the patient support service through a digital transformation for a more efficient service.

Volunteer Network fund is to mobilise a network of people in different services to go out into the community and spread the work and engage with people to discuss the misuse and overuse of antibiotics and their resistance.

Annual Lecture fund represents monies received from Pfizer towards the costs of the 2024 annual lecture.

19 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2025	Incoming resources	Resources expended	Transfers	At 31 December 2025
	£	£	£	£	£
General funds	124,202	256,689	(255,387)	-	125,504

19 Unrestricted funds **(Continued)**

Previous year:	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
General funds	56,445	282,610	(279,363)	64,510	124,202

20 Analysis of net assets between funds

	Unrestricted funds 2025	Restricted funds 2025	Total 2025
	£	£	£
At 31 December 2025:			
Tangible assets	8,638	-	8,638
Current assets/(liabilities)	116,866	169,049	285,915
	125,504	169,049	294,553

	Unrestricted funds 2024	Restricted funds 2024	Total 2024
	£	£	£
At 31 December 2024:			
Current assets/(liabilities)	124,202	265,201	389,403
	124,202	265,201	389,403

21 Related party transactions

There were no disclosable related party transactions during the year.